The Top Line

The year in biotech


Listen Later

This week on "The Top Line," Fierce Biotech staff writer Gabrielle Masson and senior editor Annalee Armstrong look back at the year in biotech, which was defined by massive layoffs across the industry. They also discuss their favorite stories of the year, including an appearance from a popstar whose reputation precedes her. 

To learn more about the topics in this episode: 

  • Biotechs end year 'trading for nothing' as investors mull 'what is IPO-able today?'
  • Fierce Biotech Layoff Tracker 2023
  • Editor's Corner—When ASCO dueled with the world's biggest pop star, Swift Biotech was ready for it
  • Alzheimer's meds are here. But for the Down syndrome community, it's still the 1980s

 

See omnystudio.com/listener for privacy information.

...more
View all episodesView all episodes
Download on the App Store

The Top LineBy Fierce Life Sciences

  • 4
  • 4
  • 4
  • 4
  • 4

4

11 ratings


More shows like The Top Line

View all
Planet Money by NPR

Planet Money

30,860 Listeners

Motley Fool Money by The Motley Fool

Motley Fool Money

3,234 Listeners

Exchanges by Goldman Sachs

Exchanges

964 Listeners

Odd Lots by Bloomberg

Odd Lots

1,987 Listeners

WSJ Tech News Briefing by The Wall Street Journal

WSJ Tech News Briefing

1,655 Listeners

The a16z Show by Andreessen Horowitz

The a16z Show

1,090 Listeners

The Readout Loud by STAT

The Readout Loud

335 Listeners

Wall Street Breakfast by Seeking Alpha

Wall Street Breakfast

1,051 Listeners

Behind the Money by Financial Times

Behind the Money

227 Listeners

The Journal. by The Wall Street Journal & Spotify Studios

The Journal.

6,093 Listeners

BioCentury This Week by BioCentury

BioCentury This Week

35 Listeners

Economics Explained by Economics Explained

Economics Explained

150 Listeners

Biotech Hangout by Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler & more

Biotech Hangout

21 Listeners

The Markets by Goldman Sachs

The Markets

77 Listeners

WSJ's Take On the Week by The Wall Street Journal

WSJ's Take On the Week

142 Listeners